[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533147":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":36,"centralContacts":40,"locations":47,"responsibleParty":148,"collaborators":45,"id":150,"slug":151,"hasResults":152,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":45,"eligibilityCriteria":156,"healthyVolunteers":152,"sex":157,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":45,"studyType":163,"phases":164,"briefSummary":166,"conditions":167,"keywords":45,"overallStatus":50,"whyStopped":45,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":161},{"fullName":5,"class":6},"Alfasigma S.p.A.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Filgotinib Dose A","EXPERIMENTAL","Dose A of filgotinib mini-tablet for participants with bodyweight (BW) 15-\\\u003C25 kg",[13],"Drug: Filgotinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Filgotinib Dose B","Dose B of filgotinib tablet for participants with BW ≥25-\\\u003C60 kg",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Filgotinib Dose C","Dose C of filgotinib tablet for participants with BW ≥60 kg",[13],[23,31],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Filgotinib","Film-coated mini-tablets administered orally once daily",[9],[29,30],"GS-6034","GLPG0634",{"type":24,"name":25,"description":32,"armGroupLabels":33,"otherNames":34},"Commercially developed film-coated tablet administered orally once daily",[15,19],[29,30,35],"Jyseleca",[37],{"name":38,"affiliation":5,"role":39},"Alfasigma Study Director","STUDY_DIRECTOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Pilar de la Torre","CONTACT","00800 7878 1345",null,"medicalinfo@alfasigma.com",[48,61,70,81,90,100,111,122,128,137],{"facility":49,"status":50,"city":51,"state":45,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":45},"CHU Amiens - Hopital Nord","RECRUITING","Amiens","80054","France","FR",{"type":56,"coordinates":57},"Point",[58,59],2.3,49.9,{"lat":59,"lon":58},{"facility":62,"status":50,"city":63,"state":45,"zip":64,"country":53,"countryCode":54,"cosmosGeoPoint":65,"geoPoint":69,"contacts":45},"Bicêtre University Hospital","Le Kremlin-Bicêtre","94270",{"type":56,"coordinates":66},[67,68],2.36073,48.81471,{"lat":68,"lon":67},{"facility":71,"status":50,"city":72,"state":45,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":45},"Children's university hospital Charité, Campus Virchow, SPZ","Berlin","13353","Germany","DE",{"type":56,"coordinates":77},[78,79],13.41053,52.52437,{"lat":79,"lon":78},{"facility":82,"status":50,"city":83,"state":45,"zip":84,"country":74,"countryCode":75,"cosmosGeoPoint":85,"geoPoint":89,"contacts":45},"Hamburger Zentrum fur Kinder und Jugendrheumatologie","Hamburg","22081",{"type":56,"coordinates":86},[87,88],9.99302,53.55073,{"lat":88,"lon":87},{"facility":91,"status":92,"city":93,"state":45,"zip":94,"country":74,"countryCode":75,"cosmosGeoPoint":95,"geoPoint":99,"contacts":45},"Asklepios Klinik Sankt Augustin GmbH","NOT_YET_RECRUITING","Sankt Augustin","53757",{"type":56,"coordinates":96},[97,98],7.197,50.77538,{"lat":98,"lon":97},{"facility":101,"status":50,"city":102,"state":45,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":110,"contacts":45},"Malopolskie Badania Kliniczne","Krakow","30-002","Poland","PL",{"type":56,"coordinates":107},[108,109],19.93658,50.06143,{"lat":109,"lon":108},{"facility":112,"status":50,"city":113,"state":45,"zip":114,"country":115,"countryCode":116,"cosmosGeoPoint":117,"geoPoint":121,"contacts":45},"Hospital Universitari Vall d'Hebron","Barcelona","08035","Spain","ES",{"type":56,"coordinates":118},[119,120],2.15899,41.38879,{"lat":120,"lon":119},{"facility":123,"status":50,"city":113,"state":45,"zip":124,"country":115,"countryCode":116,"cosmosGeoPoint":125,"geoPoint":127,"contacts":45},"Hospital Sant Joan de Deu","08950",{"type":56,"coordinates":126},[119,120],{"lat":120,"lon":119},{"facility":129,"status":50,"city":130,"state":45,"zip":131,"country":115,"countryCode":116,"cosmosGeoPoint":132,"geoPoint":136,"contacts":45},"Hospital Universitari i Politecnic La Fe","Valencia","46026",{"type":56,"coordinates":133},[134,135],-0.37966,39.47391,{"lat":135,"lon":134},{"facility":138,"status":92,"city":139,"state":45,"zip":140,"country":141,"countryCode":142,"cosmosGeoPoint":143,"geoPoint":147,"contacts":45},"Great Ormond Street Hospital","London","WC1N 3JH","United Kingdom","UK",{"type":56,"coordinates":144},[145,146],-0.12574,51.50853,{"lat":146,"lon":145},{"type":149,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR","100533147","phase-1-study-to-measure-filgotinib-in-the-blood-of-children-and-teenagers-with-arthritis-taking-filgotinib-scalesia-100533147",false,"NCT06222034","Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)","An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis","Key Inclusion Criteria:\n\n* Participant with a body mass index (BMI) within the 5th to 95th percentiles for the age and gender (based on World Health Organization BMI charts). Participant must have a minimum weight of 15 kg.\n* Participant must meet the International League of Associations for Rheumatology classification for 1 of the following categories and have, according to the investigator's judgment, moderately to severely active disease that is not adequately controlled with his\u002Fher current therapy.\n\n  * Rheumatoid factor (RF)-positive polyarthritis\n  * RF-negative polyarthritis\n  * Oligoarthritis\n  * Psoriatic arthritis\n  * Enthesis-related arthritis (ERA) Note: Historical Human leukocyte antigen B-27 (HLA-B27) results are considered appropriate for ERA diagnosis during screening.\n  * Systemic JIA with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment\n* Participant with intolerance or a history of inadequate response to at least one of the following medications for the treatment of JIA, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs and biological disease-modifying antirheumatic drugs (including methotrexate) and non-steroidal anti-inflammatory drugs for ERA and psoriatic arthritis.\n* Female participants of childbearing potential (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test.\n\nKey Exclusion Criteria:\n\n* Participant with persistent oligoarthritis.\n* Participant with undifferentiated arthritis.\n* Participant with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis).\n* Active infection that is clinically significant, as per judgment of the investigator.\n* Participant with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement).\n* Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria).\n\nNote: Other protocol defined Inclusion\u002F Exclusion criteria may apply.","ALL","8 Years","18 Years",{"count":161,"type":162},10,"ESTIMATED","INTERVENTIONAL",[165],"PHASE1","A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).",[168],"Juvenile Idiopathic Arthritis","2026-05-19",{"date":171,"type":172},"2026-05-22","ACTUAL",{"date":174,"type":172},"2024-05-13",{"date":176,"type":162},"2026-08",{"name":5,"class":6}]